Governor Inslee's Director of Life Science and Global Health Development, Maura Little, Presides Over CMC Biologics' Ribbon Cutting Ceremony Commemorating the Bioreactor 6Pack™ Manufacturing Facility

SEATTLE, BERKELEY, Calif. and COPENHAGEN, Denmark, Oct. 7, 2015 /PRNewswire/ -- CMC Biologics, Inc., a global leader in commercial manufacturing of therapeutic proteins, officially marked the opening of its first-in-class Bioreactor 6Pack™ manufacturing facility with a ribbon cutting ceremony on Wednesday, October 1, at its Bothell, Washington campus. Nearly 200 local political and business leaders attended the event. 

The Bioreactor 6Pack™ configuration consists of six 2000L single-use production bioreactors and a 2000L seed train, allowing for flexible production with scales from 2000L to12000L in a single production suite. The bioreactors can be run in single unit operations or in groups, simultaneously, sequentially or in staggered fashion to achieve our customers' desired production needs.

Director of Life Science and Global Health Development of Washington State, Maura Little, who presided over the dedication of the facility said, "I'm delighted to see Washington State's life science sector continue to grow and expand. CMC Biologics has been a tremendous partner to the local biotech community, and the Governor and I appreciate your dedication to our state economy and the life science community.  The Washington state life science sector employs more than 42,000 individuals and has become Washington's fifth largest sector, where roughly 1,000 life science organizations call home.  The life science industry will provide the people of Washington State with jobs and prosperity into the next century."

"From the beginning, our ambition has always been to be leaders in our field – using the best technology, having the best process development capabilities and supplying API for marketed drug product," remarked David Kauffmann, Chairman of the Board of CMC Biologics and Managing Director of European Equity Partners. "This expansion is a testimony that we are living by our ambition and continue to find the best solutions for our clients."

"I'd like to take this opportunity to recognize the hard work of each of our dedicated employees and the great support from our robust life science community," said Gustavo Mahler, PhD, Global Chief Operations Officer of CMC Biologics.  "This expansion is fundamental to furthering our goal of delivering commercial manufacturing solutions to our customers and lifesaving medicines to patients around the world." 

About CMC Biologics
CMC Biologics is leading the industry among CMOs in reliability, technical excellence, and quality — Right and On Time. With three facilities in the USA and Europe, the Company provides fully integrated biopharmaceutical development and manufacturing solutions to clients globally. The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical, and commercial production. The Company's wide range of integrated services includes cell line development, bioprocess development, formulation development, and comprehensive analytical testing. Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes. More detailed information can be found at www.cmcbiologics.com.

Logo - http://photos.prnewswire.com/prnh/20110502/SF93356LOGO

SOURCE CMC Biologics

Related Links

http://www.cmcbiologics.com